DexCom, Inc. (NASDAQ:DXCM) Shares Purchased by Waters Parkerson & CO. LLC

Waters Parkerson & CO. LLC increased its holdings in DexCom, Inc. (NASDAQ:DXCM) by 4.2% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 272,641 shares of the medical device company’s stock after buying an additional 10,892 shares during the quarter. DexCom comprises approximately 1.6% of Waters Parkerson & CO. LLC’s investment portfolio, making the stock its 21st largest holding. Waters Parkerson & CO. LLC owned 0.07% of DexCom worth $30,912,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Vanguard Group Inc. raised its stake in shares of DexCom by 0.3% during the 1st quarter. Vanguard Group Inc. now owns 44,603,745 shares of the medical device company’s stock valued at $6,186,539,000 after buying an additional 136,282 shares during the last quarter. Capital Research Global Investors grew its holdings in DexCom by 21.4% during the fourth quarter. Capital Research Global Investors now owns 15,296,032 shares of the medical device company’s stock worth $1,898,085,000 after acquiring an additional 2,695,296 shares during the period. Sands Capital Management LLC raised its position in DexCom by 10.2% during the fourth quarter. Sands Capital Management LLC now owns 15,058,806 shares of the medical device company’s stock valued at $1,868,647,000 after acquiring an additional 1,398,136 shares in the last quarter. Capital World Investors lifted its holdings in DexCom by 130.7% in the fourth quarter. Capital World Investors now owns 9,278,685 shares of the medical device company’s stock valued at $1,151,392,000 after acquiring an additional 5,256,092 shares during the period. Finally, Artisan Partners Limited Partnership boosted its position in DexCom by 164.8% in the 4th quarter. Artisan Partners Limited Partnership now owns 5,900,308 shares of the medical device company’s stock worth $732,169,000 after purchasing an additional 3,672,471 shares in the last quarter. 97.75% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

DXCM has been the subject of several recent research reports. Stifel Nicolaus lifted their target price on shares of DexCom from $90.00 to $100.00 and gave the company a “buy” rating in a report on Friday, August 23rd. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $145.00 price objective on shares of DexCom in a report on Tuesday, July 23rd. Morgan Stanley decreased their price objective on shares of DexCom from $120.00 to $75.00 and set an “equal weight” rating for the company in a research report on Friday, July 26th. StockNews.com cut DexCom from a “buy” rating to a “hold” rating in a research report on Monday, June 10th. Finally, Baird R W cut DexCom from a “strong-buy” rating to a “hold” rating in a report on Friday, July 26th. Seven analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, DexCom has an average rating of “Moderate Buy” and a consensus target price of $112.25.

DexCom Trading Up 3.5 %

Shares of DXCM stock opened at $71.92 on Friday. DexCom, Inc. has a fifty-two week low of $62.34 and a fifty-two week high of $142.00. The company has a debt-to-equity ratio of 1.00, a quick ratio of 2.48 and a current ratio of 2.82. The stock’s fifty day moving average is $79.06 and its two-hundred day moving average is $109.99. The firm has a market capitalization of $28.60 billion, a P/E ratio of 46.40, a PEG ratio of 2.12 and a beta of 1.18.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Thursday, July 25th. The medical device company reported $0.43 earnings per share for the quarter, topping analysts’ consensus estimates of $0.39 by $0.04. The firm had revenue of $1 billion for the quarter, compared to analyst estimates of $1.04 billion. DexCom had a net margin of 16.95% and a return on equity of 31.41%. DexCom’s quarterly revenue was up 15.3% on a year-over-year basis. During the same period in the previous year, the business posted $0.34 earnings per share. Research analysts expect that DexCom, Inc. will post 1.69 earnings per share for the current fiscal year.

Insider Transactions at DexCom

In related news, EVP Sadie Stern sold 426 shares of the stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $29,457.90. Following the completion of the sale, the executive vice president now owns 75,451 shares of the company’s stock, valued at $5,217,436.65. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, EVP Michael Jon Brown sold 652 shares of the stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $69.55, for a total value of $45,346.60. Following the completion of the sale, the executive vice president now owns 66,249 shares of the company’s stock, valued at approximately $4,607,617.95. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Sadie Stern sold 426 shares of the firm’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $29,457.90. Following the sale, the executive vice president now directly owns 75,451 shares of the company’s stock, valued at approximately $5,217,436.65. The disclosure for this sale can be found here. Insiders have sold a total of 2,483 shares of company stock worth $201,708 in the last ninety days. Insiders own 0.30% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.